Check out this terrific story featuring Andrés Henao, MD, FIDSA as he shares his experience teaching a course on tropical infectious diseases and learning from fellow experts at La Universidad Nacional de la Amazonía Peruana in Iquitos, Peru! 🌎📚

CU Department of Medicine

news.cuanschutz.edu/department-of-…

🔍🦠 Exploring brucellosis- This study from Iran focuses on arthritis and sacroiliitis cases, uncovering key symptoms and diagnostic insights. 🩺📊 Read more @ journals.sagepub.com/doi/full/10.11… #Brucella

Study in 🇵🇰 looking at clinical features, outcomes in pulm mucormycosis finds higher mortality association in patients with T'cytopenia, on immunosuppression , on mech ventilation. Read more @ journals.sagepub.com/doi/full/10.11…

A systematic review examined fungal infections in adults post-COVID-19. Mucor spp., PJP and Aspergillus spp. were prevalent, impacting patient presentation and prognosis differently than acute or non-COVID-19 cases. 🦠🍄 Read more @
journals.sagepub.com/doi/full/10.11…

Thrilled to announce our collaboration with Therapeutic Advances in Rare Disease for a Special Collection on Rare Infectious Diseases! 🌐📚 Submit your research by Sep 30, 2024. Details: bit.ly/3uHbuRD

🚨 New review - Dive into the world of Powassan virus (POWV) – a ticking time bomb ⏰ for severe neuroinvasive illness transmitted by pesky Ixodes ticks. Learn about the clinical picture, surge in cases, & future scope #Powassan 🧠🦠
journals.sagepub.com/doi/full/10.11…

Aqui en el ultimo dia de #ESCMIDGlobal viendo los pósters. Aqui con sdinfectologia apoyando a la Dra Fernandez donde presenta #Mabscessus pna en 2 pts inmunocompotentes APInfectología Rita Rojas #WomenInID #WeAreID #mentoria #sponsoring

#ECCMID2024 talk by Jon Salmanton-García 🔎🍄🩸💉🦠:
'Costs and resource utilization patterns in surgical site infections: A pre #COVID19 perspective from France, Germany, Spain, and the United Kingdom'

Now on YouTube: youtube.com/watch?v=grZL_R…
#escmidglobal2024

New study delves into institution-specific data on urosepsis causative agents, crucial for refining empiric antibiotic therapy. Tailoring treatment to local bacterial profiles enhances patient care and combatting antimicrobial resistance. journals.sagepub.com/doi/10.1177/20…

IPT Intermitent Preventive Therapy
Pirimetamina-sulfadoxina to all pregnant women in second semester, living in areas from High to moderate prevalence of Malaria. IPT has reduced 57% the incidence of low birth weight in the countries implementing IPTp strategies. #ECCMID2024

#ESCMIDGlobal2024 excellent presentation on the use of social media for digital learning by Erin Murchan Bonura, MD, MCR, FIDSA featuring my dear friend Laila Woc-Colburn, MD who happens to be sitting next to me during the session 😃

One on Africa's leading mycologists Dr Rita Oladele of University of Lagos 🇳🇬

It's hard enough managing fungal infection in high income countries.

Becomes almost impossible in low resource settings.

#ECCMID2024 #ESCMIDGlobal2024 ESCMID

Why #teamwork between #microbiology and #clinic is needed...?

Sylvie van der Werf exposes it clearly

🤰Exciting News! Introducing our Special Collection on Infections in Pregnancy with Women's Health Journal.Seeking high-quality original research, reviews, meta-analyses, and systematic reviews. Look forward to contributions!
Deadline April 30,2024
bit.ly/48mZKCI

All set for #eccmid2024 #ESCMIDGlobal , the largest Infectious Diseases and Microbiology conference of the year

I'll be tweeting highlights over the next 4 days - will be following on line initially but will be joining soon in Barcelona!

Today! At 12.00, #P0337 , #COVID19 in #haematological patients in a nutshell.

Poster area ESCMID

ESGREV European Hematology Association #ECCMID #ESCMIDGlobal2024

This study by Priya Nori MD, FSHEA, FIDSA et al assessed feasibility of dalbavancin as for complex gram-positive infections and shows promising results. #Dalbavancin
Read more @ journals.sagepub.com/doi/full/10.11…

Exciting news! 🚀 Launching a Special Collection on 'Harm Reduction at the Intersection of Infectious Diseases and Substance Use' 📚🔬 Submit your papers by Sep 30, 2024.
More Details @ journals.sagepub.com/page/tai/call-…

🔬Investigating the use of mNGS in non-immunocompromised adult patients with unexplained fever. 🌡️ Found at least one organism in 65.3% of cases, mostly viruses. 💊 Positive clinical impact in 40.3% of cases. Marilyne Daher M. Rizwan Sohail, MD #mNGS journals.sagepub.com/doi/full/10.11…

🦟 Investigating malaria vaccine acceptance in 🇺🇬.432 participants enrolled.💉 91.4% had good acceptance, with factors like knowing a child who died of malaria and preferring injection route associated with acceptance. #MalariaVaccine Okot Jerom
journals.sagepub.com/doi/full/10.11…